←
Debbe McCall47,325 posts
Debbe McCall avatar

Debbe McCall

@DebbeMcCall

#AFib patient researcher, advocate & DSMB. Follow/favorite/tweets ≠ endorse.

◷ Joined February 2014▧ 22,824 Photos and videos
ISLAA avatar
⟳ Debbe McCall retweeted
ISLAA@IslaaFoundation·Nov 14

Registration for in-person and remote attendance is now open for ISLAA 2027. Free CME and ABIM MOC credits available #AFib #EPeeps

Post attachmentPost attachment
Debbe McCall avatar
Debbe McCall@DebbeMcCall·Nov 13

Predictors of Functional Recovery After Stroke in 2014 and 2024: A Retrospective Study From a Portuguese Reference Rehabilitation Center buff.ly/hHmzyHq

Jason Andrade avatar
⟳ Debbe McCall retweeted
Jason Andrade@DrJasonAndrade·Nov 12

Please enjoy the All Jason Panel discussing the PIF-PAF-PFA study.

NEW EPISODE OF THE LEAD! [Ep. 177] A Discussion of the PIFPAF-PFA Randomized Clinical Trial 🎙️ Host: Jason T. Jacobson, MD, FHRS (@DrRhthm) 🎤 Guests: Jason G. Andrade, MD, FHRS (@DrJasonAndrade) and Jason D. Roberts, MD Listen on your preferred podcast platform ➡️ bit.ly/48bpxNn #EPeeps #medpod #podcast #CardioTwitter #EPTwitter #PodcastAndChill

EP Lab Digest avatar
⟳ Debbe McCall retweeted
EP Lab Digest@EPLabDigest·Nov 10

EPLD's Lead Extraction Topic Center delivers in-depth articles and up-to-date news dedicated to this growing field. Explore how Henry Ford Health manages complex lead extractions, hybrid OR resources, and urgent cases in this Spotlight Interview. hubs.ly/Q04CVqbY0

Post attachment
Jason Andrade avatar
⟳ Debbe McCall retweeted
Jason Andrade@DrJasonAndrade·Nov 9

The COAST-AF study’s was presented at AHA this weekend. LVZ ablation has a mixed history in the realm of AF ablation with 50% of the 17 RCTs being negative. But there is a nuance there. We know LVZ are associated with worse outcomes but the difference in study result probably reflects the “how” we deal with them. Study targeting homogenization, anchoring lesions, and functional substrates have generally been more positive than those where “isolation” is performed. I suspect the future of persistent AF ablation will represent a convergence of personalized approaches examining substrate and function. This is an important contribution from Pablo Nery and team. Congrats to the team.

Presented at #ScientificSessions26: In a prespecified principal subgroup of patients with low-voltage areas, adjunctive low-voltage area ablation with pulmonary vein isolation was associated with lower atrial arrhythmia recurrence and lower atrial fibrillation burden than pulmonary vein isolation alone. These findings indicate that substrate-guided ablation may have relevance for treatment selection in patients with persistent #AtrialFibrillation who have low-voltage areas identified during mapping. ja.ma/4iFimDE

Post attachment
ISLAA avatar
⟳ Debbe McCall retweeted
ISLAA@IslaaFoundation·Nov 9

Registration for in-person and remote attendance is now open for ISLAA 2027. shorturl.at/HATTL Free CME and ABIM MOC credits available. - via #Whova Event Platform

Post attachment
Nassir Marrouche avatar
⟳ Debbe McCall retweeted
Nassir Marrouche@nmarrouche·Nov 9

For nearly 20 years, our teams have worked to understand #AFib through the biology of the #atrial substrate. What began as a hypothesis around atrial fibrosis is becoming increasingly clear. The question may no longer be simply: PVI versus substrate ablation? The more important question is: Which AF patient has a modifiable atrial substrate, where is it, and can we reliably eliminate it? DECAAF I established that atrial fibrosis matters and strongly predicts ablation outcome. DECAAF II then tested MRI-guided fibrosis ablation in persistent AF. The overall trial was neutral, but the mechanistic lesson was important: identifying fibrosis alone was not enough. Intended ablation did not always translate into durable scar, and benefit appeared related to both disease extent and effective substrate coverage. IDEAL-AF and COAST-AF now add another piece. IDEAL-AF selected only patients with meaningful low-voltage substrate for randomization. When that substrate was specifically targeted with clear electrical endpoints, outcomes improved substantially over PVI alone. COAST-AF tells a similar story. The overall trial was negative, but among patients who actually had low-voltage areas, substrate ablation significantly improved outcomes. Patients without demonstrable substrate did not appear to benefit. These studies may therefore be defining the same biology from different directions: No significant atrial substrate → PVI may be enough. A demonstrable, modifiable atrial myopathy → PVI alone may be inadequate. Advanced, diffuse disease → simply adding more ablation may not overcome the biology. The next phase of AF ablation should move beyond “more ablation” toward precision substrate therapy: identify the AF fibrosis/myopathy phenotype, select the right patient, define the abnormal tissue accurately, and ensure that it is truly modified or isolated. The future is not empiric substrate ablation. It is targeting the AF substrate in the right patient, at the right stage of disease. @chris_sohns @PrashSanders @peterkistler3 @S_NarayanMD @Phiso_de @netta_doc @TinaBaykaner @DrRoderickTung @Ed_Gerst @shivkumarmd @Siddmann @gautamsand @drjohnm @TulaneTriad

Presented at #ScientificSessions26: In a prespecified principal subgroup of patients with low-voltage areas, adjunctive low-voltage area ablation with pulmonary vein isolation was associated with lower atrial arrhythmia recurrence and lower atrial fibrillation burden than pulmonary vein isolation alone. These findings indicate that substrate-guided ablation may have relevance for treatment selection in patients with persistent #AtrialFibrillation who have low-voltage areas identified during mapping. ja.ma/4iFimDE

Post attachment
Prash Sanders avatar
⟳ Debbe McCall retweeted
Prash Sanders@PrashSanders·Nov 10

Really important data - there is almost 2 years difference in the longevity of the same devices (some) between clinics - do we need some standardisation and centralised monitoring #CHRD @UniofAdelaide @CentralAdlLHN @SAHealth @PaceMateLIVE @HRSonline @thecsanz @SanaAlkhatib9

Centralized Remote Monitoring Enables Detection of Institutional Outliers in Cardiac Implantable Electronic Device Longevity: A Case for National Benchmarking #OpenAccess @ShaunEvansMD @PrashDanders heartrhythmjournal.com/artic…

Post attachment